West Pharmaceutical Services Inc

WST

Equity

ISIN null / Valor 112491

New York Stock Exchange, Inc (2025-11-18)

USD 260.14-0.87%

West Pharmaceutical Services Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

West Pharmaceutical Services Inc. is a prominent player in the pharmaceutical and healthcare industry, specializing in the development and manufacturing of packaging components and delivery systems for injectable drugs and healthcare products. The company's expertise lies in creating solutions that enhance the efficiency and reliability of drug administration, focusing on serving the needs of pharmaceutical, biotechnology, and generic drug industries. West Pharmaceutical Services is recognized for its commitment to quality and safety, adhering to rigorous international standards such as ISO 9001 and ISO 13485, which are critical for medical device manufacturers. These standards underscore the company's dedication to implementing effective quality management systems, ensuring the highest level of product quality and compliance with global regulatory requirements. By leveraging its extensive knowledge in human factors engineering and its application in the development of combination products—those that include both a device and a drug or a device and a biologic—West Pharmaceutical Services plays a crucial role in advancing drug delivery technologies that aim to improve patient outcomes and enhance the overall user experience.

Summarized from source with an LLMView SourceSector: Healthcare

Sales Performance

Q2 2025 net sales reached $766.5 million, showing a 9.2% increase with a notable organic net sales growth of 6.8%. The Proprietary Products segment led the momentum with a 10.7% increase, while the Contract-Manufactured Products segment, which accounts for 19% of total sales, recorded a 3.0% rise.

Earnings Growth

For the second quarter of 2025, West Pharmaceutical Services Inc reported a diluted EPS of $1.82, up from $1.51 in Q2 2024, and an adjusted diluted EPS of $1.84 versus $1.52, underscoring improved profitability across the quarter.

Guidance Update

The company raised its full-year 2025 net sales guidance to a range of $3.040 billion to $3.060 billion from the previous $2.945 billion to $2.975 billion, along with an upward revision of its adjusted-diluted EPS guidance to $6.65 to $6.85, reflecting anticipatory tailwinds, including favorable foreign exchange movements.

Dividend Announcement

Additionally, West Pharmaceutical Services Inc approved a fourth-quarter 2025 dividend of $0.22 per share, affirming its commitment to delivering shareholder value with the upcoming payment scheduled for November 19, 2025.

Summarized from source with an LLMView Source

Key figures

-15.3%1Y

15.6%3Y

-7.52%5Y

Performance

63.3%1Y

46.7%3Y

41.7%5Y

Volatility